ArticleNeuro-oncology advances
High human cytomegalovirus antigen expression in pediatric medulloblastoma tissue is associated with poor event-free survival.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multiscale systems modelling of communication networks in brain metastasis.Experimental & molecular medicine · 2026Review
- Integrated Multi-Omics Analysis Reveals an HCMV-Associated Late-Gene Signature Associated with Poor Survival in Pediatric Group 3 Medulloblastoma.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite advancements in treatment, 5-year survival for medulloblastoma (MB) remains 60%-70%. Human cytomegalovirus (HCMV) has been implicated as an oncomodulator in MB, but its impact on survival has not been explored. This study evaluates HCMV expression in pediatric MB tissue and its association with molecular risk groups and survival. Methods: A retrospective study of pediatric MB cases (≤19 years) from 2007 to 2023 was conducted using the WHO 2021 classification, the Northcott brain-tumor classifier, and the SIOP-Europe/ERN PaedCan risk stratification. HCMV immediate-early (HCMV-IE) and late-antigen (HCMV-LA) expression were assessed by optimized immunohistochemistry, and whole-genome sequencing (WGS) data from 20 tumors were analyzed for viral gene expression. Results: Forty-five patients (mean age 8.2 years; 22% ≤3 years) were included: WNT (18%), SHH TP53-wildtype (18%), and non-WNT/non-SHH (64%). Twenty percent of MB belonged to low-risk, 33% to standard-risk, and 47% to high-risk (HR-MB) groups. Four tumors exhibited MYC/N amplification. HCMV-LA positivity was found in 84% of cases, with 53% showing high expression (≥25% of cells). Cox-regression identified HR-MB (HR = 4.197, Conclusions: This study provides the first evidence linking high HCMV-LA expression to adverse outcomes and high-risk molecular features in pediatric MB. UL88 emerged as the most strongly expressed HCMV gene across MB samples. These findings suggest a potential prognostic and therapeutic role for HCMV in MB, warranting validation in larger, prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.